Archive for the ‘misconduct investigations’ Category
Denis de Jesus Lima Guerra, a co-author on 11 chemistry papers that were retracted in 2011 for suspicions of fraud, has lost his position at the Federal University of Mato Grosso (UFMT).
We have a second retraction from a group of neuroscience researchers in Belgium who discovered fatal errors in their work on how the brain sets about the task of reading written language. Spoiler alert: Turns out those errors weren’t errors after all.
As we reported back in May, the group, from the University of Leuven, was unable to replicate certain fMRI findings in a November 2012 article in Neuroscience. At the time, Hans P. Op de Beeck, who led the group, told us: Read the rest of this entry »
Two researchers in Denmark are guilty of scientific dishonesty, the Danish Committees on Scientific Dishonesty (DCSD, Danish acronym UVVU) has concluded.
In July, the DCSD said in a draft report that Bente Klarlund Pedersen had acted in a “scientifically dishonest” and “grossly negligent” manner. She — and many of her defenders — responded by saying that while she had made mistakes, she had not committed misconduct. Here’s a key quote from a letter her attorney wrote to the committee: Read the rest of this entry »
We’re always glad to have guest posts, and here’s one from François-Xavier Coudert, reporting from France.
As we reported the other day, a Nature editorial suggested that police involvement might be an appropriate response to research misconduct. The French seem to agree, based on reports in the media there, as Coudert writes:
A husband-wife team of French odontology researchers at l’université Paul-Sabatier in Toulouse have been on trial in that country for research misconduct. Christine Marchal-Sixou, an associate professor, faces a charge of plagiarism, and Michel Sixou, full professor and dean of the faculty of dental medicine until September, has been charged with complicity. Read the rest of this entry »
Nearly six months after first expressing concern about the validity of a 2010 paper on multiple sclerosis, Nature Medicine has retracted the article for containing “erroneous” data — which in this case don’t seem to have existed, making them more fabricated than wrong.
The paper, “Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease,” came from a group led by Jingwu Zhang, who at the time ran GlaxoSmithKline’s Research and Development Center in Shanghai.
The Journal of Clinical Anesthesia has a retraction of a 2006 paper by a group from Columbia University that, to our minds, is the poster child for how not to handle such things.
The article, “Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery,” was written by Robert J. Frumento, Helene G. Logginidou, Staffan Wahlander, Gebhard Wagener, Hugh R. Playford and Robert N. Sladen, who now is chief of critical care at the institution. The paper has been cited 30 times, according to Thomson Scientific’s Web of Knowledge.
The Lancet has retracted a study of Novartis’ blood pressure drug valsartan (Diovan) that has been subject to an investigation following the retraction of a related study earlier this year.
Here’s the detailed notice for “Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study”: Read the rest of this entry »
A Danish researcher has responded to a draft report of the Danish Committees on Scientific Dishonesty (DCSD) that found she had acted in a “scientifically dishonest” and “grossly negligent” manner.
Bente Klarlund Pedersen, a University of Copenhagen researcher, has published with Milena Penkowa, four of whose papers have been retracted following investigations. In the press, she argued that while she had made mistakes, she had not committed misconduct.
The 57-page letter from Klarlund Pedersen’s attorney to the DCSD responds in detail to the critique of her work, including twelve papers. This passage from the summary gathers the arguments together: Read the rest of this entry »
An Australian university has put a hold on trials of an experimental drug for skin cancer whose main developer has been dogged by charges of research misconduct for several years.
The Australian Broadcasting Corporation is reporting that the University of New South Wales has suspended trials of the drug, DZ13, while it investigates the work of Levon Khachigian, who is leading the studies.
According to the news organization, Khachigian and his group were cleared by the school in two prior inquiries. However, additional accusations of misconduct — specifically involving image manipulation and misuse — prompted a third investigation.
We’ve found four retractions of Khachigian’s studies, from the Journal of Biological Chemistry and Biochemical and Biophysical Research Communications, between 2009 and 2010 (before the launch of Retraction Watch).
They are: Read the rest of this entry »
The new retraction appears in Experimental Neurology. Here’s the notice for “M-CSF deficiency leads to reduced metallothioneins I and II expression and increased tissue damage in the brain stem after 6-aminonicotinamide treatment”: Read the rest of this entry »